Key Takeaways
- Peptide Sciences shut down March 6, 2026 — a three-sentence notice, no warning, no explanation
- Three forces converged: FDA enforcement, pharmaceutical litigation, and quality testing failures
- The company was doing $7.4M/month in sales at the time of closure
- The shutdown was "voluntary" — but came during the most aggressive regulatory crackdown in industry history
- Reopening is unlikely — the regulatory environment has only intensified
At approximately 2:00 PM Eastern on March 6, 2026, the largest research peptide vendor in the United States posted a three-sentence notice on its homepage and went dark.
No advance warning. No guidance for customers with pending orders. No explanation beyond the word "voluntary."
Peptide Sciences — the vendor that thousands of researchers treated as a default, generating an estimated $7.4 million per month in online sales — was done.
This is the story of what happened and why it matters.
The Shutdown
The notice was minimal. Peptide Sciences stated it had "voluntarily decided to shut down operations and discontinue the sale of all research products." A brief thank-you to customers. Nothing more.
Within hours, customer support channels stopped responding. Pending orders were not fulfilled. Store credit balances became worthless. The Reddit peptide communities lit up with confusion, frustration, and speculation.
But the shutdown didn't happen in a vacuum. It was the culmination of forces that had been building for over a year.
Force 1: FDA Enforcement Accelerated
The FDA's enforcement against research peptide vendors escalated dramatically between 2024 and 2026.
December 2024: FDA issued warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for selling unapproved drug products.
June 2025: FDA agents raided Amino Asylum's warehouse, seizing inventory and shutting down operations overnight. This was the first physical raid on a major peptide vendor — a significant escalation from warning letters.
September 2025: FDA issued 50+ warning letters to GLP-1 compounding pharmacies in a single month.
December 2025: Paradigm Peptides' founders pleaded guilty to federal charges after investigation revealed their SARM products contained testosterone, a controlled substance. The $1.79 million forfeiture from Tailor Made Compounding LLC's earlier prosecution had already established that federal penalties were severe.
January 2026: Science.bio announced permanent closure.
March 6, 2026: Peptide Sciences shut down.
The pattern was clear. What started as warning letters became raids, then criminal prosecutions. The FDA was also deploying AI to scrape vendor websites for hidden dosing information that contradicted "research use only" disclaimers — a technological escalation that made the traditional grey-market model increasingly risky.
For a vendor generating $7.4 million monthly, the calculus was straightforward: the potential legal consequences now outweighed the revenue.
Force 2: Pharmaceutical Litigation
While the FDA enforced federal drug law, pharmaceutical companies opened a second front through civil litigation.
April 2025: Eli Lilly filed federal lawsuits against telehealth companies distributing unapproved tirzepatide, including Fella Health and Mochi Health. The suits alleged trademark infringement and distribution of unapproved drugs.
August 2025: Novo Nordisk filed lawsuits against 14 defendants — pharmacies and vendors compounding or distributing semaglutide products.
These lawsuits didn't target Peptide Sciences directly, but they established legal precedent that any vendor selling GLP-1 analogues was exposed to litigation from companies with unlimited legal budgets.
Peptide Sciences carried both semaglutide and tirzepatide. These were among their most popular products. Every sale created potential liability.
The pharmaceutical companies also entered exclusive agreements with telehealth platforms, prohibiting those platforms from working with compounding pharmacies — further squeezing the market for non-branded GLP-1 products.
Force 3: Quality Testing Failures
The final factor was closer to home.
Independent third-party testing — particularly from Janoshik Analytical — revealed quality inconsistencies across the Peptide Sciences catalog. The most damning results involved retatrutide:
- 37 tested samples received failing grades between December 2024 and March 2026
- At least one counterfeit detection was flagged
- Results raised questions about whether quality control had deteriorated as demand scaled
For a vendor that built its reputation on quality, these results were devastating. Researchers who had defended Peptide Sciences as "the gold standard" suddenly had data suggesting otherwise.
The testing failures didn't cause the shutdown alone. But they removed the quality reputation that had been Peptide Sciences' primary defense against competitors — and made the risk-reward calculation even less favorable.
Timeline: The Path to Shutdown
| Date | Event |
|---|---|
| Dec 2024 | FDA warning letters to multiple peptide vendors |
| Dec 2024 | Janoshik begins publishing failing retatrutide test results |
| Apr 2025 | Eli Lilly sues telehealth companies over tirzepatide |
| Jun 2025 | FDA raids Amino Asylum warehouse |
| Aug 2025 | Novo Nordisk sues 14 semaglutide distributors |
| Sep 2025 | FDA issues 50+ warning letters to GLP-1 compounders |
| Dec 2025 | Paradigm Peptides founders plead guilty; Science.bio announces closure |
| Jan 2026 | Science.bio permanently closes |
| Mar 6, 2026 | Peptide Sciences shuts down |
| Mar 16, 2026 | HHS announces 14 banned peptides return to legal compounding |
